Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Momelotinib - Sierra Oncology

Drug Profile

Momelotinib - Sierra Oncology

Alternative Names: CYT-387; GS-0387; Momelotinib dihydrochloride

Latest Information Update: 02 Aug 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cytopia Research
  • Developer Sierra Oncology
  • Class Antineoplastics; Antirheumatics; Benzamides; Morpholines; Pyrimidines; Small molecules
  • Mechanism of Action ACVR1 protein inhibitors; Janus kinase 1 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myeloproliferative disorders
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Essential thrombocythaemia; Myelofibrosis; Myeloproliferative disorders; Pancreatic cancer; Polycythaemia vera
  • Preclinical Rheumatoid arthritis
  • No development reported Non-small cell lung cancer

Most Recent Events

  • 11 Jun 2020 Updated pooled efficacy and adverse events data from the phase III SIMPLIFY trials in Myelofibrosis, Essential thrombocythaemia and Polycythaemia vera presented at the 25th Congress of the European Haematology Association (EHA-2020)
  • 03 Jun 2020 Preclinical trials in Rheumatoid arthritis in USA (unspecified route)
  • 03 Jun 2020 Pharmacodynamics data from preclinical trial in Rheumatoid arthritis presented at the 21st Annual Congress of the European League Against Rheumatism (EULAR-2020)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top